Russia’s Ministry of Health has authorised clinical trials of a modified version of Russia’s Sputnik V vaccine against COVID-19, the data from the registry of approved clinical trials has shown.
“The goal of the clinical study: to evaluate the safety, reactogenicity and immunogenicity of the Gam-COVID-Vac vector vaccine [Sputnik V] for the prevention of coronavirus infection caused by the SARS-CoV-2 virus with a modified antigenic profile in adult volunteers,” the line in the registry has shown.
The clinical study will be completed on December 31, 2024. As many as 100 volunteers are expected to participate in the trials, according to the registry.
An authorisation has also been issued to carry out clinical trials of a modified coronavirus vaccine for children aged 12-17, and the trials will be completed on December 31, 2024, the registry has shown.
Alexander Gintsburg, the director of Moscow-based Gamaleya National Center for Epidemiology and Microbiology, which developed the Sputnik V vaccine, told Sputnik in April that vaccines against COVID-19 should be modified every 9-10 months to be effective.
